Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kudzu resistant starch (KRS) is a dietary supplement and prebiotic derived from the kudzu plant (*Pueraria lobata*). It is characterized by its resistance to digestion in the small intestine, allowing it to reach the colon where it undergoes fermentation by gut microbiota. KRS has demonstrated therapeutic potential in metabolic disorders, including non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Its mechanism involves the modulation of gut microbiota diversity, enhancement of intestinal barrier function (via increased expression of zonula occludens-1 and mucin 2), and suppression of systemic inflammation through the down-regulation of the LPS/TLR4 signaling pathway. Additionally, KRS regulates lipid metabolism and improves insulin sensitivity by modulating signaling pathways such as IRS-1/PI3K/AKT/Glut4 and PPAR-γ.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kudzu resistant starch.